Comparative Pharmacology
Head-to-head clinical analysis: CYCLOPHOSPHAMIDE versus VIVIMUSTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOPHOSPHAMIDE versus VIVIMUSTA.
CYCLOPHOSPHAMIDE vs VIVIMUSTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell cycle nonspecific cytotoxicity. It requires hepatic metabolism by cytochrome P450 (CYP2B6, CYP3A4, CYP2C9) to form active metabolites, phosphoramide mustard and acrolein, which alkylate DNA and inhibit protein synthesis.
VIVIMUSTA is a nitrogen mustard alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death.
400-600 mg/m2 IV every 2-4 weeks; or 50-100 mg/m2 orally daily for 7-14 days; or 1-2 g/m2 IV as a single dose every 3-4 weeks.
100 mg/m2 intravenously over 30 minutes on days 1-3 of a 21-day cycle.
None Documented
None Documented
Clinical Note
moderateCyclophosphamide + Verteporfin
"Cyclophosphamide may increase the cardiotoxic activities of Verteporfin."
Clinical Note
moderateCyclophosphamide + Digoxin
"Cyclophosphamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCyclophosphamide + Digitoxin
"Cyclophosphamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCyclophosphamide + Deslanoside
Terminal elimination half-life: 4-8 hours in adults with normal renal function; prolonged in renal impairment (up to 15 hours) and in children.
Terminal elimination half-life is 12 hours (range 10-14 h) in adults with normal renal function; prolonged to 24-36 h in moderate renal impairment (CrCl 30-50 mL/min).
Renal: approximately 30-60% of dose excreted unchanged in urine; biliary/fecal excretion is minimal (<5%).
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Category D/X
Category C
Alkylating Agent
Alkylating Agent
"Cyclophosphamide may decrease the cardiotoxic activities of Deslanoside."